Jul 18,2023

An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma

The EMulate Therapeutics Voyager™ is a simple, wearable, home-use device that uses an alternating electromagnetic field to alter biologic signaling within cells. The objective of this study is to assess the safety/feasibility of the Voyager in the treatment of recurrent glioblastoma (rGBM). In this study, patients with rGBM were treated with Voyager as monotherapy or in combination with standard chemotherapy at the Investigator's discretion. Safety was assessed by incidence of adverse events associated with the Voyager. A total of 75 patients were enrolled and treated for at least one day with the Voyager (safety population). Device-related adverse events were uncommon and generally did not result in interruption or withdrawal from treatment. The data support the safety and feasibility of the Voyager for the treatment of rGBM. Further prospective study of the device is warranted.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Jul 06,2023 TOP STORY

Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics

Tempus today announced a new collaboration to develop a companion diagnostic (CDx) test with TScan Therapeutics, a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of cancer patients. The collaboration supports TScan’s screening protocol for its Phase 1 solid tumor clinical trial which is designed to enable customized mixtures of TCR-Ts to be administered to patients based on tumor antigen positivity and intact HLA expression. TScan plans to enroll patients with solid tumors including non-small cell lung cancer, melanoma, head and neck cancer, ovarian cancer, and cervical cancer.

COLLABORATION PARTNERSHIP

#r&d

#cdx

View Analyst & Ambassador Comments
Go to original news
Jul 04,2023

AI and CRISPR Precisely Control Gene Expression

A study published in Nature Biotechnology demonstrates that artificial intelligence (AI) can accurately predict the on- and off-target activity of CRISPR tools that target RNA. The researchers combined deep learning with CRISPR screens to precisely control gene expression, offering potential for developing new CRISPR-based therapies. The AI model, called TIGER (Targeted Inhibition of Gene Expression via guide RNA design), outperformed previous models in predicting both on-target and off-target activity of RNA-targeting CRISPRs. The study highlights the potential of AI to enhance the development of RNA-targeting therapies in biomedicine, and to tackle the aberrant gene expressions seen in cancer, which leads to tumor growth.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 03,2023 TOP STORY

Study backs Lunit’s AI-powered cancer diagnostics

Lunit, a South Korean medical AI company, conducted a study published in the journal Radiology that demonstrated the effectiveness of its AI-powered cancer diagnostic solution. The study involved 30 doctors who analyzed 120 chest X-rays with and without the assistance of Lunit's AI model. The high-accuracy AI model significantly improved radiologists' performance, with an AUROC of 0.82 compared to 0.75 without AI. The study emphasized the importance of accurate AI models in enhancing diagnostic accuracy and fostering acceptance of AI in medical practices. Lunit aims to advance cancer diagnostics through innovative technology.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jun 29,2023

Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study

Improved markers for predicting recurrence are needed to stratify patients with localised (stage I–III) renal cell carcinoma after surgery for selection of adjuvant therapy. The new study published on the Lancet Digital Health Journal presents a novel assay integrating three modalities—clinical, genomic, and histopathological—to improve the predictive accuracy for localised renal cell carcinoma recurrence. In this retrospective analysis and validation study, they developed a histopathological whole-slide image (WSI)-based score using deep learning allied to digital scanning of conventional haematoxylin and eosin-stained tumour tissue sections, to predict tumour recurrence in a development dataset of 651 patients with distinctly good or poor disease outcome. The multimodal recurrence score was validated in 1625 patients from the independent validation dataset and 418 patients from The Cancer Genome Atlas set. The primary outcome measured was the recurrence-free interval (RFI). The results of the study shows that multimodal recurrence score is a practical and reliable predictor that can add value to the current staging system for predicting localised renal cell carcinoma recurrence after surgery, and this combined approach more precisely informs treatment decisions about adjuvant therapy.

CLINICAL STUDY

#ml

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jun 27,2023

Massive Bio and Datavant Expand Partnership to Integrate Datavant’s Medical Record Retrieval Capabilities to Revolutionize Patient Care and Clinical Research

Massive Bio and Datavant, the leader in helping organizations securely connect data, are thrilled to announce an expanded partnership that leverages Datavant’s national scale in medical record retrieval and Massive Bio’s expertise in AI-driven clinical trial matching to accelerate clinical research and improve patient care in cancer. This expanded partnership builds upon an earlier pilot that enabled Massive Bio to request, retrieve, and digitally deliver clinical data with higher reliability, faster speed and greater coverage across sites of care, thus significantly improving patient outcomes while ensuring compliance and data privacy. With this expanded partnership, Massive Bio will integrate Datavant’s medical record retrieval capabilities into Massive Bio’s operations in order to expedite the identification of potential clinical trial participants and speed up time to insight in clinical research.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Jun 28,2023

Preventing Cervical Cancer with Digital Health

In England alone, around 2,700 women are diagnosed with cervical cancer each year. However, the NHS screening programme saves approximately 5,000 lives annually. One remarkable success story in promoting cervical cancer screenings is the project commissioned by NHS England and North of England CSU. The project used iPLATO's Population Health Service, part of HUMA, to send text message reminders to women who were due for their screening appointment. Through this initiative, attendance rates for cervical cancer screenings increased by 6.3% in London. The project reduced the invite-to-appointment time by 17 days.

PRODUCT

#rpm

View Analyst & Ambassador Comments
Go to original news
Jun 29,2023

Lung cancer screening rolled out nationwide in the UK

Landmark news for lung cancer outcomes this week: a national targeted screening programme was announced in the UK, giving an expected 9,000 people each year a fighting chance against lung cancer through early diagnosis. The programme will build upon NHS England’s Targeted Lung Health Checks, currently running across 43 sites. Implementing lung cancer screening is highly complex and demanding for healthcare systems. The NHS has successfully piloted such a programme: the Targeted Lung Health Checks (TLHCs), which invited eligible people for a free check of their lungs in easily accessible, mobile CT units. Since 2018, the initiative has boosted early diagnosis in deprived areas, catching 2,000 lung cancers, 76% at an early stage. Speaking about the TLHCs in the House of Commons, Secretary of State for Health and Social Care Steve Barclay specifically mentioned how Aidence's artificial intelligence (AI) tool, Veye Lung Nodules is supporting radiologists to report on the large volumes of chest scans.

View Analyst & Ambassador Comments
Go to original news
Jun 29,2023

Jasper Health Partners with Wellnecity to Bring Digital Oncology Platform to Self-Insured Employers

Jasper Health is thrilled to announce the availability of its platform for Wellnecity self-insured employer clients. The platform aims to revolutionize the way cancer patients and their caregivers receive support by offering one-on-one human-led psychosocial coaching, personalized guidance, and innovative digital planning tools. Wellnecity’s extensive network of self-insured employer clients will now have access to Jasper Health’s ComPass offering tailored for employers that may have a smaller population of covered lives, as well as gig economy employees who may not have access to a cancer care benefit otherwise. Key features of the Jasper Health ComPass offering for Wellnecity includes human-led psychosocial coaching, personalized guidance, and digital planning tools.

COLLABORATION PARTNERSHIP

#institution

#rpm

#coaching

View Analyst & Ambassador Comments
Go to original news
Jun 22,2023

Employer-focused Carrum Health partners with care navigation company apree health

Carrum Health, a digital marketplace for employers to purchase bundled healthcare services, announced its Center of Excellence network will be integrated into healthcare navigation platform apree health's partner network for employees to access affordable surgical and cancer care. Data-driven healthcare navigation platform apree health is a combination of health navigation company Castlight Health and coordinated primary care company Vera Whole Health. The Washington-based company offers digital engagement and advanced primary care via its platform dubbed apree foundation, a cloud native healthcare data and technology platform that aggregates healthcare data. California-based Carrum Health provides a value-based digital platform for self-funded employers. The company offers a Center of Excellence network that gives employees access to a care specialist who coordinates and guides them through the surgical and cancer treatment process.

COLLABORATION PARTNERSHIP

#institution

#virtual care

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY